Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?

Journal of General Internal Medicine

Volumn 24, Issue 5, 2009, Pages 543-549

  Eckman, Mark H ^a   Greenberg, Steven M ^b   Rosand, Jonathan ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticoagulant therapy; Atrial fibrillation; Decision analysis; Genetic testing; Pharmacogenetics; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C9; WARFARIN;

ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; EMBOLISM; GENE FREQUENCY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS;

EID: 67349146039     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-009-0927-7     Document Type: Article

References (64)

1. V Fuster LE Ryden DS Cannom 2006 ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 7 e257 354 (Pubitemid 43948016)
2. DE Singer GW Albers JE Dalen AS Go JL Halperin WJ Manning 2004 Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 suppl 429S 456S (Pubitemid 39302603)
3. SG Rockson GW Albers 2004 Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation J Am Coll Cardiol 43 6 929 35 (Pubitemid 38401065)
4. S Sanderson J Emery J Higgins 2005 CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis Genet Med 7 2 97 104 (Pubitemid 40261834)
5. T Yin T Miyata 2007 Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives Thromb Res 120 1 1 10 (Pubitemid 46601582)
6. M Wadelius LY Chen N Eriksson 2007 Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 1 23 34 (Pubitemid 46421137)
7. MW Linder 2001 Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin Clin Chim Acta 308 1-2 9 15 (Pubitemid 32537605)
8. M Muszkat S Blotnik A Elami I Krasilnikov Y Caraco 2007 Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions Clin Ther 29 3 427 437 (Pubitemid 46907283)
9. DM Adcock C Koftan D Crisan FL Kiechle 2004 Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation Arch Pathol Lab Med 128 12 1360 1363 (Pubitemid 39627472)
10. GP Aithal CP Day PJ Kesteven AK Daly 1999 Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 9154 717 9 (Pubitemid 29103806)
11. MK Higashi DL Veenstra LM Kondo 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy Jama 287 13 1690 1698 (Pubitemid 34289221)
12. M Margaglione D Colaizzo G D'Andrea 2000 Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 5 775 778
13. J Taube D Halsall T Baglin 2000 Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 5 1816 1819 (Pubitemid 30661066)
14. LE Visser RH van Schaik M van Vliet 2004 The risk of bleeding complications in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon Thromb Haemost 92 1 61 66 (Pubitemid 39010868)
15. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin. Clin Pharmacol Ther. 2007.
16. LE Visser M van Vliet RH van Schaik 2004 The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon Pharmacogenetics 14 1 27 33 (Pubitemid 38183959)
17. Gage BF. Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program. 2006:467-73.
18. F Kamali M Pirmohamed 2006 The future prospects of pharmacogenetics in oral anticoagulation therapy Br J Clin Pharmacol 61 6 746 751 (Pubitemid 43794805)
19. E Krynetskiy P [tmp] McDonnell 2007 Building individualized medicine: prevention of adverse reactions to warfarin therapy J Pharmacol Exp Ther 322 2 427 434
20. EA Millican PA Lenzini PE Milligan 2007 Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 110 5 1511 1515 (Pubitemid 47443966)
21. MS Ogg P Brennan T Meade SE Humphries 1999 CYP2C93 allelic variant and bleeding complications Lancet 354 9184 1124 (Pubitemid 29452841)
22. RG Hart O Benavente R [tmp] McBride LA Pearce 1999 Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 7 492 501 (Pubitemid 29482392)
23. RG Hart LA Pearce MI Aguilar 2007 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 857 867
24. CS Landefeld RJ Beyth 1993 Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 3 315 328 (Pubitemid 23270290)
25. BF Gage Y Yan PE Milligan 2006 Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 3 713 719 (Pubitemid 43290267)
26. SD Fihn M [tmp] McDonell D Martin 1993 Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 7 511 520
27. MC Fang AS Go EM Hylek 2006 Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study J Am Geriatr Soc 54 8 1231 1236 (Pubitemid 44166528)
28. C van Walraven RG Hart DE Singer 2002 Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis Jama 288 19 2441 2448 (Pubitemid 35340540)
29. AR Wintzen H de Jonge EA Loeliger GT Bots 1984 The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study Ann Neurol 16 5 553 558 (Pubitemid 15211689)
30. D Woo JP Broderick 2002 Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation Neurosurg Clin N Am 13 3 265 279
31. AJ Furlan JP Whisnant LR Elveback 1979 The decreasing incidence of primary intracerebral hemorrhage: a population study Ann Neurol 5 4 367 373
32. RG Hart BS Boop DC Anderson 1995 Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses Stroke 26 8 1471 1477
33. D Woo R Kaushal R Chakraborty 2005 Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage Stroke 36 9 1874 1879 (Pubitemid 41266517)
34. GW Albers DG Sherman DR Gress JE Paulseth P Petersen 1991 Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials Ann Neurol 30 4 511 518
35. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-57.
36. J He PK Whelton B Vu MJ Klag 1998 Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials Jama 280 22 1930 1935 (Pubitemid 28559811)
37. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996;156(4):409-16.
38. C Patrono B Coller GA FitzGerald J Hirsh G Roth 2004 Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 234S 264S (Pubitemid 39297956)
39. A Detsky G Naglie M Krahn D Naimark D Redelmeier 1997 Primer on medical decision analysis: Part 1-Getting started Med Decis Making 17 123 125 (Pubitemid 27157026)
40. J Lau JP Kassirer SG Pauker 1983 Decision Maker 3.0. Improved decision analysis by personal computer Med Decis Making 3 1 39 43
41. J Rosand MH Eckman KA Knudsen DE Singer SM Greenberg 2004 The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage Arch Intern Med 164 8 880 884 (Pubitemid 38520629)
42. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116(1):6-12.
43. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators [see comments]. Ann Intern Med. 1992;116(1):1-5.
44. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158(12):1316-20.
45. BF Gage AD Waterman W Shannon M Boechler MW Rich MJ Radford 2001 Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation Jama 285 22 2864 2870 (Pubitemid 32537350)
46. Broderick JP. Natural history of primary intracerebral hemorhage. In: Whisnant JP, ed. Population-based clinical epidemiology of stroke. Oxford: Butterworth-Heinmann; 1993: 154-173.
47. BF Gage AD Waterman W Shannon M Boechler MW Rich MJ Radford 2001 Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation Jama 285 22 2864 2870 (Pubitemid 32537350)
48. SJ Connolly J Pogue J Eikelboom 2008 Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 20 2029 2037
49. Health care savings from personalized medicine using genetic testing: the case of warfarin. http://www.aei-brookings.org/publications/abstract.php?pid= 1127. 1/15/2008.
50. JH You FW Chan RS Wong G Cheng 2004 The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis Thromb Haemost 92 3 590 597 (Pubitemid 39248016)
51. DL Veenstra 2007 The cost-effectiveness of warfarin pharmacogenomics J Thromb Haemost 5 9 1974 1975 (Pubitemid 47288958)
52. MH Eckman J Rosand SM Greenberg BF Gage 2009 Cost-Effectiveness of Pharmacogenetic-Based Dosing of Warfarin in Patients with Atrial Fibrillation Ann Intern Med 150 73 83
53. MC Fang AS Go Y Chang 2007 Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 8 700 705 (Pubitemid 47176507)
54. CR Lee JA Goldstein JA Pieper 2002 Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 3 251 263 (Pubitemid 34596790)
55. MJ Stubbins LW Harries G Smith MH Tarbit CR Wolf 1996 Genetic analysis of the human cytochrome P450 CYP2C9 locus Pharmacogenetics 6 5 429 439 (Pubitemid 26380099)
56. HG Xie HC Prasad RB Kim CM Stein 2002 CYP2C9 allelic variants: ethnic distribution and functional significance Adv Drug Deliv Rev 54 10 1257 1270 (Pubitemid 35284252)
57. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997;157(11):1237-40.
58. S Penado M Cano O Acha JL Hernandez JA Riancho 2002 Stroke severity in patients with atrial fibrillation Am J Med 112 7 572 574 (Pubitemid 34518317)
59. M Man-Son-Hing A Laupacis 2002 Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation Arch Intern Med 162 5 541 550 (Pubitemid 34193541)
60. TO Tengs M Yu E Luistro 2001 Health-related quality of life after stroke a comprehensive review Stroke 32 4 964 972 (Pubitemid 32285167)
61. EM Hylek DE Singer 1994 Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 11 897 902 (Pubitemid 24179151)
62. D Woo LR Sauerbeck BM Kissela 2002 Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study Stroke 33 5 1190 1195 (Pubitemid 34517033)
63. G Palareti N Leali S Coccheri 1996 Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy Lancet 348 9025 423 428
64. BF Gage AB Cardinalli DK Owens 1996 The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life Arch Intern Med 156 16 1829 1836 (Pubitemid 26295228)